Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015 (2015), Article ID 251403, 9 pages
http://dx.doi.org/10.1155/2015/251403
Review Article

Serum and Urine Biomarkers for Human Renal Cell Carcinoma

1Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, Urology Unit ICOT, Sapienza University of Rome, Via Franco Faggiana 1668, 04100 Latina, Italy
2Department of Translational Medical Science, University of Naples “Federico II”, Via Sergio Pansini 5, 80131 Naples, Italy
3Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, Pathology Unit ICOT, Sapienza University of Rome, Via Franco Faggiana 1668, 04100 Latina, Italy
4Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Corso della Repubblica 79, 04100 Latina, Italy

Received 30 December 2014; Accepted 26 March 2015

Academic Editor: Donald H. Chace

Copyright © 2015 A. L. Pastore et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. T. Lee, J. Katz, P. A. Fearn, and P. Russo, “Mode of presentation of renal cell carcinoma provides prognostic information,” Urologic Oncology, vol. 7, no. 4, pp. 135–140, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Levi, J. Ferlay, C. Galeone et al., “The changing pattern of kidney cancer incidence and mortality in Europe,” BJU International, vol. 101, no. 8, pp. 949–958, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Lipworth, R. E. Tarone, and J. K. McLaughlin, “The epidemiology of renal cell carcinoma,” Journal of Urology, vol. 176, no. 6, pp. 2353–2358, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. H. van Poppel, L. da Pozzo, W. Albrecht et al., “A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma,” European Urology, vol. 59, no. 4, pp. 543–552, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. W. C. Huang, E. B. Elkin, A. S. Levey, T. L. Jang, and P. Russo, “Partial nephrectomy vs. radical nephrectomy in patients with small renal tumors: is there a difference in mortality and cardiovascular outcomes?” Journal of Urology, vol. 181, no. 1, pp. 55–61, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. E. H. Kim, Y. S. Tanagho, S. B. Bhayani, N. E. Saad, B. M. Benway, and R. S. Figenshau, “Percutaneous cryoablation of renal masses: Washington University experience of treating 129 tumours,” BJU International, vol. 111, no. 6, pp. 872–879, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. T. M. Wah, H. C. Irving, W. Gregory, J. Cartledge, A. D. Joyce, and P. J. Selby, “Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours,” BJU International, vol. 113, no. 3, pp. 416–428, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Audenet, D. R. Yates, G. Cancel-Tassin, O. Cussenot, and M. Rouprêt, “Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine,” BJU International, vol. 109, no. 12, pp. 1864–1870, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Pischon, P. H. Lahmann, H. Boeing et al., “Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC),” International Journal of Cancer, vol. 118, no. 3, pp. 728–738, 2006. View at Publisher · View at Google Scholar
  10. C. R. Daniel, A. J. Cross, B. I. Graubard et al., “Large prospective investigation of meat intake, related mutagens, and risk of renal cell carcinoma,” The American Journal of Clinical Nutrition, vol. 95, no. 1, pp. 155–162, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Xu, Y. Qi, J. Zhang et al., “The impact of smoking on survival in renal cell carcinoma: a systematic review and meta-analysis,” Tumor Biology, vol. 35, no. 7, pp. 6633–6640, 2014. View at Publisher · View at Google Scholar
  12. K. M. Sanfilippo, K. M. McTigue, C. J. Fidler et al., “Hypertension and obesity and the risk of kidney cancer in 2 large cohorts of US men and women,” Hypertension, vol. 63, no. 5, pp. 934–941, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Hu, Y. Mao, K. White et al., “Renal cell carcinoma and occupational exposure to chemicals in Canada,” Occupational Medicine, vol. 52, no. 3, pp. 157–164, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Schwarz, S. Vatandaslar, S. Merkel, and H. Haller, “Renal cell carcinoma in transplant recipients with acquired cystic kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 2, no. 4, pp. 750–756, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Bausch, C. Jilg, S. Gläsker et al., “Renal cancer in von Hippel-Lindau disease and related syndromes,” Nature Reviews Nephrology, vol. 9, no. 9, pp. 529–538, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. C. G. Przybycin, C. Magi-Galluzzi, and J. K. McKenney, “Hereditary syndromes with associated renal neoplasia: a practical guide to histologic recognition in renal tumor resection specimens,” Advances in Anatomic Pathology, vol. 20, no. 4, pp. 245–263, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. H. L. Kim, A. S. Belldegrun, D. G. Freitas et al., “Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis,” Journal of Urology, vol. 170, no. 5, pp. 1742–1746, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. H. B. Palsdottir, S. Hardarson, V. Petursdottir et al., “Incidental detection of renal cell carcinoma is an independent prognostic marker: results of a long-term, whole population study,” The Journal of Urology, vol. 187, no. 1, pp. 48–53, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. O. Hélénon, J. M. Correas, C. Balleyguier, M. Ghouadni, and F. Cornud, “Ultrasound of renal tumors,” European Radiology, vol. 11, no. 10, pp. 1890–1901, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. M. J. Leveridge, P. J. Bostrom, G. Koulouris, A. Finelli, and N. Lawrentschuk, “Imaging renal cell carcinoma with ultrasonography, CT and MRI,” Nature Reviews Urology, vol. 7, no. 6, pp. 311–325, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Lebret, J. E. Poulain, V. Molinie et al., “Percutaneous core biopsy for renal masses: indications, accuracy and results,” Journal of Urology, vol. 178, no. 4, part 1, pp. 1184–1188, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. M. K. Gospodarowicz, D. Miller, P. A. Groome, F. L. Greene, P. A. Logan, and L. H. Sobin, “The process for continuous improvement of the TNM classification,” Cancer, vol. 100, no. 1, pp. 1–5, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. S. P. Kim, A. L. Alt, C. J. Weight et al., “Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort,” Journal of Urology, vol. 185, no. 6, pp. 2035–2039, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Novara, V. Ficarra, A. Antonelli et al., “Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed?” European Urology, vol. 58, no. 4, pp. 588–595, 2009. View at Publisher · View at Google Scholar
  25. S. Waalkes, F. Becker, A. J. Schrader et al., “Is there a need to further subclassify pT2 renal cell cancers as implemented by the revised 7th TNM version?” European Urology, vol. 59, no. 2, pp. 258–263, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Bedke, S. Buse, M. Pritsch et al., “Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences,” BJU International, vol. 103, no. 10, pp. 1349–1354, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. J. R. Srigley, B. Delahunt, J. N. Eble et al., “The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia,” American Journal of Surgical Pathology, vol. 37, no. 10, pp. 1469–1489, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. K. A. Keegan, C. W. Schupp, K. Chamie, N. J. Hellenthal, C. P. Evans, and T. M. Koppie, “Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage,” Journal of Urology, vol. 188, no. 2, pp. 391–397, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. W. R. Sukov, C. M. Lohse, B. C. Leibovich, R. H. Thompson, and J. C. Cheville, “Clinical and pathological features associated with prognosis in patients with papillary renal cell carcinoma,” Journal of Urology, vol. 187, no. 1, pp. 54–59, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. G. P. Paner, M. B. Amin, I. Alvarado-Cabrero et al., “A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with fuhrman nuclear grade,” The American Journal of Surgical Pathology, vol. 34, no. 9, pp. 1233–1240, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Kutikov and R. G. Uzzo, “The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth,” Journal of Urology, vol. 182, no. 3, pp. 844–853, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. S. MacLennan, M. Imamura, M. C. Lapitan et al., “Systematic review of oncological outcomes following surgical management of localised renal cancer,” European Urology, vol. 61, no. 5, pp. 972–993, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. V. Ficarra, G. Novara, S. Secco et al., “Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery,” European Urology, vol. 56, no. 5, pp. 786–793, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. M. N. Simmons, C. B. Ching, M. K. Samplaski, C. H. Park, and I. S. Gill, “Kidney tumor location measurement using the C index method,” The Journal of Urology, vol. 183, no. 5, pp. 1708–1713, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. H.-J. Tan, J. S. Wolf Jr., Z. Ye, J. T. Wei, and D. C. Miller, “Population-level comparative effectiveness of laparoscopic versus open radical nephrectomy for patients with kidney cancer,” Cancer, vol. 117, no. 18, pp. 4184–4193, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. S. MacLennan, M. Imamura, M. C. Lapitan et al., “Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer,” European Urology, vol. 62, no. 6, pp. 1097–1117, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. H. J. Bekema, S. MacLennan, M. Imamura et al., “Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma,” European Urology, vol. 64, no. 5, pp. 799–810, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. J. H. M. Blom, H. van Poppel, J. M. Maréchal et al., “Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881,” European Urology, vol. 55, no. 1, pp. 28–34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Usui, I. G. Glezerman, S. P. Salvatore, C. B. Chandran, C. D. Flombaum, and S. V. Seshan, “Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature,” Human Pathology, vol. 45, no. 9, pp. 1918–1927, 2014. View at Publisher · View at Google Scholar
  40. B. Escudier, L. Albiges, and G. Sonpavde, “Optimal management of metastatic renal cell carcinoma: current status,” Drugs, vol. 73, no. 5, pp. 427–438, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. D. F. McDermott, “Immunotherapy of metastatic renal cell carcinoma,” Cancer, vol. 115, supplement 10, pp. 2298–2305, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. P. I. Karakiewicz, A. Briganti, F. K.-H. Chun et al., “Multi-institutional validation of a new renal cancer-specific survival nomogram,” Journal of Clinical Oncology, vol. 25, no. 11, pp. 1316–1322, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Zigeuner, G. Hutterer, T. Chromecki et al., “External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology,” European Urology, vol. 57, no. 1, pp. 102–111, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Isbarn and P. I. Karakiewicz, “Predicting cancer-control outcomes in patients with renal cell carcinoma,” Current Opinion in Urology, vol. 19, no. 3, pp. 247–257, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. P. I. Karakiewicz, N. Suardi, U. Capitanio et al., “A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma,” European Urology, vol. 55, no. 2, pp. 287–295, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. C. Eichelberg, K. Junker, B. Ljungberg, and H. Moch, “Diagnostic and prognostic molecular marker for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability,” European Urology, vol. 55, no. 4, pp. 851–863, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. J. S. Lam, A. J. Pantuck, A. S. Belldegrun, and R. A. Figlin, “Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials,” Clinical Cancer Research, vol. 13, no. 2, pp. 703s–708s, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Kondo, “Inconvenient truth: Cancer biomarker development by using proteomics,” Biochimica et Biophysica Acta—Proteins and Proteomics, vol. 1844, no. 5, pp. 861–865, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Gupta, A. Venkatesh, S. Ray, and S. Srivastava, “Challenges and prospects for biomarker research: a current perspective from the developing world,” Biochimica et Biophysica Acta, vol. 1844, no. 5, pp. 899–908, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. E. Rodríguez-Suárez, J. Siwy, P. Zürbig, and H. Mischak, “Urine as a source for clinical proteome analysis: from discovery to clinical application,” Biochimica et Biophysica Acta—Proteins and Proteomics, vol. 1844, no. 5, pp. 884–898, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. R. Rajandram, N. Y. Yap, J. Pailoor et al., “Tumour necrosis factor receptor-associated factor-1 (TRAF-1) expression is increased in renal cell carcinoma patient serum but decreased in cancer tissue compared with normal,” Pathology, vol. 46, no. 6, pp. 518–522, 2014. View at Publisher · View at Google Scholar
  52. M. Katsogiannou, C. Andrieu, and P. Rocchi, “Heat shock protein 27 phosphorylation state is associated with cancer progression,” Frontiers in Genetics, vol. 5, article 346, 2014. View at Publisher · View at Google Scholar
  53. N. M. A. White, O. Masui, L. V. DeSouza et al., “Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma,” Oncotarget, vol. 5, no. 2, pp. 506–518, 2014. View at Google Scholar · View at Scopus
  54. A. R. de Vivar Chevez, J. Finke, and R. Bukowski, “The Role of Inflammation in Kidney Cancer,” in Inflammation and Cancer, vol. 816 of Advances in Experimental Medicine and Biology, pp. 197–234, Springer, Basel, Switzerland, 2014. View at Publisher · View at Google Scholar
  55. A. Mittal, B. Poudel, D. R. Pandeya, S. P. Gupta, B. Sathian, and S. K. Yadav, “Serum amyloid a as an independent prognostic factor for renal cell carcinoma—a hospital based study from the western region of nepal,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 5, pp. 2253–2255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Fischer, G. Theil, R. Hoda, and P. Fornara, “Serum amyloid A: a biomarker for renal cancer,” Anticancer Research, vol. 32, no. 5, pp. 1801–1804, 2012. View at Google Scholar · View at Scopus
  57. M. de Martino, T. Klatte, C. Seemann et al., “Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC),” BJU International, vol. 111, no. 8, pp. E348–E353, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Steffens, A. Köhler, R. Rudolph et al., “Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients,” BMC Cancer, vol. 12, article 399, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Corti, M. Franzini, A. Paolicchi, and A. Pompella, “Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting,” Anticancer Research, vol. 30, no. 4, pp. 1169–1181, 2010. View at Google Scholar
  60. S. L. Hofbauer, K. I. Stangl, M. de Martino et al., “Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma,” British Journal of Cancer, vol. 111, no. 8, pp. 1526–1531, 2014. View at Publisher · View at Google Scholar
  61. R. S. Wong, “Apoptosis in cancer: from pathogenesis to treatment,” Journal of Experimental & Clinical Cancer Research, vol. 30, article 87, 2011. View at Publisher · View at Google Scholar
  62. F. Wang, J. Lin, and R. Xu, “The molecular mechanisms of TRAIL resistance in cancer cells: help in designing new drugs,” Current Pharmaceutical Design, vol. 20, no. 42, pp. 6714–6122, 2014. View at Google Scholar
  63. D. Toiyama, N. Takaha, M. Shinnoh et al., “Significance of serum tumor necrosis factor-related apoptosis-inducing ligand as a prognostic biomarker for renal cell carcinoma,” Molecular and Clinical Oncology, vol. 1, no. 1, pp. 69–74, 2013. View at Google Scholar
  64. F. Tas, S. Karabulut, I. Yildiz, and D. Duranyildiz, “Clinical significance of serum M30 and M65 levels in patients with breast cancer,” Biomedicine & Pharmacotherapy, vol. 68, no. 8, pp. 1135–1140, 2014. View at Publisher · View at Google Scholar
  65. I. Yildiz, F. Sen, L. Kilic et al., “Serum m65 as a biomarker for metastatic renal cell carcinoma,” Clinical Genitourinary Cancer, vol. 11, no. 3, pp. 290–296, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. I. J. Frew and H. Moch, “A clearer view of the molecular complexity of clear cell renal cell carcinoma,” Annual Review of Pathology, vol. 10, no. 1, pp. 263–289, 2015. View at Publisher · View at Google Scholar
  67. T. Tanaka, H. Kitamura, T. Torigoe et al., “Autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 is a potential serological marker for renal cell carcinoma,” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 5, pp. 789–794, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. J. Pastorek and S. Pastorekova, “Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use,” Seminars in Cancer Biology, vol. 31, pp. 52–64, 2015. View at Publisher · View at Google Scholar
  69. M. Takacova, M. Bartosova, L. Skvarkova et al., “Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma,” Oncology Letters, vol. 5, no. 1, pp. 191–197, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. B. Nisman, V. Yutkin, H. Nechushtan et al., “Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy,” Urology, vol. 76, no. 2, pp. 513.e1–513.e6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. P. D'Arcy, X. Wang, and S. Linder, “Deubiquitinase inhibition as a cancer therapeutic strategy,” Pharmacology & Therapeutics, vol. 147, pp. 32–54, 2015. View at Publisher · View at Google Scholar
  72. M. de Martino, K. Hoetzenecker, H. J. Ankersmit et al., “Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis,” British Journal of Cancer, vol. 106, no. 5, pp. 904–908, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. F. P. Schena, F. P. Selvaggi, L. Gesualdo, and M. Battaglia, Malattie del rene e delle vie urinarie, McGraw-Hill, 4th edition, 2008.
  74. K. Papworth, A. Bergh, K. Grankvist, B. Ljungberg, J. Sandlund, and T. Rasmuson, “Osteopontin but not parathyroid hormone-related protein predicts prognosis in human renal cell carcinoma,” Acta Oncologica, vol. 52, no. 1, pp. 159–165, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. A. di Carlo, D. Terracciano, A. Mariano, A. Oliva, M. D'Armiento, and V. Macchia, “Role of cytokeratins, nuclear matrix proteins, Lewis antigen and epidermal growth factor receptor in human bladder tumors,” International Journal of Oncology, vol. 23, pp. 757–762, 2003. View at Publisher · View at Google Scholar
  76. K. Kaya, S. Ayan, G. Gokce, H. Kilicarslan, E. Yildiz, and E. Y. Gultekin, “Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma,” Scandinavian Journal of Urology and Nephrology, vol. 39, no. 1, pp. 25–29, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. G. Ozer, M. Altinel, B. Kocak, A. Yazicioglu, and F. Gonenc, “Value of urinary NMP-22 in patients with renal cell carcinoma,” Urology, vol. 60, no. 4, pp. 593–597, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Huang, E. Rhee, H. Patel, E. Park, and J. Kaswick, “Urinary NMP-22 and renal cell carcinoma,” Urology, vol. 55, no. 2, pp. 227–230, 2000. View at Publisher · View at Google Scholar · View at Scopus
  79. D. R. Flower, “The lipocalin protein family: structure and function,” Biochemical Journal, vol. 318, no. 1, pp. 1–14, 1996. View at Google Scholar · View at Scopus
  80. A. Di Carlo, “The enigmatic role of lipocalin 2 in human cancer. The multifunctional protein neutrophil gelatinase-associated lipocalin (NGAL) and its ambiguous role in human neoplasias,” Prevention & Reseatch, vol. 2, 2012. View at Publisher · View at Google Scholar
  81. L. Yan, N. Borregaard, L. Kjeldsen, and M. A. Moses, “The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL): modulation of MMP-9 activity by NGAL,” The Journal of Biological Chemistry, vol. 276, no. 40, pp. 37258–37265, 2001. View at Publisher · View at Google Scholar · View at Scopus
  82. A. Di Carlo, “Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in sera and urine of patients with kidney tumors,” Oncology Letters, vol. 5, no. 5, pp. 1677–1681, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. J. J. Morrissey, A. N. London, M. C. Lambert, and E. D. Kharasch, “Sensitivity and specificity of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 for the diagnosis of renal cell carcinoma,” The American Journal of Nephrology, vol. 34, no. 5, pp. 391–398, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. A. di Carlo, “Matrix metalloproteinase-2 and -9 in the sera and in the urine of human oncocytoma and renal cell carcinoma,” Oncology Reports, vol. 28, no. 3, pp. 1051–1056, 2012. View at Publisher · View at Google Scholar · View at Scopus
  85. J. J. Morrissey, A. N. London, J. Luo, and E. D. Kharasch, “Urinary biomarkers for the early diagnosis of kidney cancer,” Mayo Clinic Proceedings, vol. 85, no. 5, pp. 413–421, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. J. J. Morrissey and E. D. Kharasch, “The specificity of urinary aquaporin 1 and perilipin 2 to screen for renal cell carcinoma,” Journal of Urology, vol. 189, no. 5, pp. 1913–1920, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. J. J. Morrissey, J. Mobley, J. Song et al., “Urinary concentrations of aquaporin-1 and perilipin-2 in patients with renal cell carcinoma correlate with tumor size and stage but not grade,” Urology, vol. 83, no. 1, pp. 256.e9–256.e14, 2014. View at Publisher · View at Google Scholar · View at Scopus